No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CYTK Cytokinetics
- 66.290
- -1.260-1.87%
Close Apr 22 16:00 ET
- 66.110
- -0.180-0.27%
Post 19:16 ET
6.95BMarket Cap-12163P/E (TTM)
67.900High65.665Low1.18MVolume67.900Open67.550Pre Close78.55MTurnover1.14%Turnover RatioLossP/E (Static)104.77MShares110.25052wk High-17.98P/B6.90BFloat Cap25.98052wk Low--Dividend TTM104.08MShs Float110.250Historical High--Div YieldTTM3.31%Amplitude3.050Historical Low66.323Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts' Top Healthcare Picks: Cytokinetics (CYTK), Ultragenyx Pharmaceutical (RARE)
This Weight-loss ETF Has Performed Well in Its First Five Months. How Does It Compare With Cheaper Alternatives?
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM.
EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
Cytokinetics(CYTK.US) Officer Sells US$2.42 Million in Common Stock
$Cytokinetics(CYTK.US)$ Officer Malik Fady Ibraham sold 32,605 shares of common stock on Apr 9, 2024 at an average price of $74.31 for a total value of $2.42 million.Source: Announcement What is state
Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing
Fady Ibraham Malik, Executive Vice President, Research & Development, on April 09, 2024, sold 32,605 shares in Cytokinetics (CYTK) for $2,422,918. Following the Form 4 filing with the SEC, Malik has c
Comments
Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x %$Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x %$Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
2
CEO's belief in the company's potential to grow independently may have led to a 3% stock dip. Speculation around a Novartis takeover, and its withdrawal, could have swayed investor sentiment.
1
Sunday Update Mar 3
I'm going to try something new. I'm going to make a Sunday post so that it can be read before the market opens. I hope to still do my update before the market opens on Monday, I always want to see how futures move overnight.
This new thing I'm trying will be some random thoughts about the market. How to use some features on moomoo (a request by some) to do research and develop trading levels. To show this I will introduce some stocks iam in or will be starting positions in.
...
This new thing I'm trying will be some random thoughts about the market. How to use some features on moomoo (a request by some) to do research and develop trading levels. To show this I will introduce some stocks iam in or will be starting positions in.
...
+36
55
18
Truist analyst Srikripa Devarakonda views the recent weakness in Cytokinetics' stock as a buying opportunity and maintains a buy rating and $86 price target on the stock. Devarakonda continues to see Cytokinetics as a potential M&A target.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg